EARLY BREAST CANCER
Clinical trials for EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a Chemo-Free combo beat early breast cancer without the harsh side effects?
Disease control OngoingThis study tests whether a chemotherapy-free combination of targeted drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer. About 393 adults with early-stage disease will receive these drugs before and after surgery. The goal is to see…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New pill aims to keep early breast cancer from returning
Disease control OngoingThis study tests a new drug called giredestrant against standard hormone therapies in over 4,000 people with early-stage, hormone-sensitive breast cancer. The goal is to see if giredestrant is better at stopping the cancer from coming back. Participants take the drug daily for se…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could a pill replace chemo for some breast cancers?
Disease control OngoingThis study tests whether a combination of two pills (letrozole and abemaciclib) works as well as standard chemotherapy before surgery for women with a common type of early breast cancer (HR-positive, HER2-negative). About 200 women with high or intermediate risk will be randomly …
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Spanish Breast Cancer Research Group • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Could a lighter chemo work just as well for some breast cancers?
Disease control OngoingThis study tests a less intense chemotherapy combination for people with early-stage HER2-positive breast cancer. The goal is to see if a milder regimen (paclitaxel, trastuzumab, and pertuzumab) can clear the cancer before surgery as effectively as the standard stronger regimen, …
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Hope for young moms: breast cancer treatment pause studied for safe pregnancy
Disease control OngoingThis study looks at whether young women with early-stage, hormone-sensitive breast cancer can safely pause their hormone therapy for up to two years to try to get pregnant. It involves 518 women aged 18 to 42 who have already been on hormone therapy for 18 to 30 months. The goal …
Matched conditions: EARLY BREAST CANCER
Phase: NA • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New hope for early breast cancer: drug combo may keep cancer away longer
Disease control OngoingThis large phase 3 study tests whether adding ribociclib to standard hormone therapy can help prevent breast cancer from returning in people with hormone receptor-positive, HER2-negative early breast cancer. Over 5,000 women and men are participating. The goal is to see if the co…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Breast cancer drug comparison study halted before it began
Disease control TerminatedThis study aimed to see if a new drug called EG1206A works as well as the approved drug Perjeta for people with HER2-positive early breast cancer. Both were given with trastuzumab and chemotherapy before and after surgery. However, the study was withdrawn before enrolling any par…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: EirGenix, Inc. • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
AI reads old slides to predict breast cancer return
Knowledge-focused OngoingThis study looks at whether an artificial intelligence (AI) program can accurately predict if early-stage breast cancer will come back. Researchers will analyze stored tumor slides from 2,200 women who had ER-positive, HER2-negative breast cancer. The AI's predictions will be com…
Matched conditions: EARLY BREAST CANCER
Sponsor: Spotlight Medical • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC